Synonyms: example 27 [WO2018144620] | FT-011 | FT011 | SHP-627
Compound class:
Synthetic organic
Comment: Asengeprast is the INN for a G protein-coupled receptor 68 (GPR68) antagonist with anti-inflammatory potential. We obtained the chemical structure and proposed mechanism of action from INN proposed list 130 (released Feb. 2024). This structure matched to clinical lead FT001 via PubChem, which has proposed anti-inflammatory and anti-fibrotic actions that may be of benefit across a range of human diseases [1-3,6]. Asengeprast's structure was claimed in patent WO2018144620 in 2019 [4].
|
|
No information available. |
Summary of Clinical Use |
FT001 was progressed as a potential therpeutic for autoimmune systemic sclerosis by Certa Therapeutics. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04647890 | Effects of FT011 in Systemic Sclerosis | Phase 2 Interventional | Certa Therapeutics |